13 hrs ago | AmericanBankingNews.com
Canaccord Genuity Analysts Reaffirm a "Buy" Rating on Protalix BioTherapeutics
Protalix BioTherapeutics 's stock had its "buy" rating reaffirmed by research analysts at Canaccord Genuity in a report issued on Monday.
Protalix Reinforces Case For Taliglucerase Alfa; Healthcare Sector Volume Keeps Rising
Protalix BioTherapeutics, Inc. , announced that new clinical data on taliglucerase alfa would be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held this week in San Diego, California.
Protalix Announces New Clinical Data on Taliglucerase Alfa to be...
Protalix BioTherapeutics, Inc. , announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held February 8-10 in San Diego, California.
Protalix BioTherapeutics: It's All About The Technology
Protalix's novel bioreactor plant cell system, based on disposable plastic vials, is the first of its kind.
Protalix Announces New Clinical Data on Taliglucerase Alfa to be...
Protalix BioTherapeutics, Inc. , announced today that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held February 8-10 in San Diego, California.